CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard ...

We retrospectively analyzed clinicopathologic data of 98 patients with MCL treated at our center in the past 10 years. STATA 13.0 was used for overall survival (OS) and event-free survival (EFS) ...

Please provide your email address to receive an email when new articles are posted on . Pre-transplant immune checkpoint inhibitors improved survival in relapsed Hodgkin lymphoma compared with ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda The cohort included 103 patients (63.1% female, 36.9% ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard ...

NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...